Site Close-out

Site close-out is an important stage in clinical trial management that occurs when trial-related activities at an investigator site are being completed or terminated. The purpose of site close-out is to confirm that outstanding trial activities have been appropriately addressed and that records, investigational products and other trial materials are managed according to the protocol, sponsor procedures and applicable regulatory requirements.

Close-out activities should provide appropriate documentation that the site has completed its trial responsibilities and that arrangements are in place for continued record retention and any required follow-up.

Completion of Trial Activities

Before a site is closed, the sponsor and investigator site should confirm that applicable trial activities have been completed or appropriately addressed.

Depending on the trial, this may include confirming participant status, completion of required follow-up, resolution of outstanding issues and submission of required information.

The last participant’s last visit may represent an important operational milestone, but site close-out may involve additional activities after participant visits have ended.

Review and Finalisation of Trial Data

Outstanding trial data should be reviewed and appropriately addressed before finalisation.

This may include completion of required CRFs or eCRFs, resolution of outstanding data queries, review of relevant source data and reconciliation of important trial information.

The extent of source data review and source data verification should follow the trial’s monitoring approach and identified risks rather than automatically requiring verification of all source data.

Investigational Product Accountability

Final accountability for investigational products should be confirmed during site close-out.

Records should enable appropriate reconciliation of investigational products received, dispensed or administered, returned by participants and remaining at the site.

Unused investigational products should be returned to the sponsor or undergo another authorised disposition, such as destruction, when appropriate and permitted by applicable requirements.

Final disposition should be appropriately documented.

For more information on investigational product receipt, storage, dispensing, reconciliation and disposition, see Drug Accountability.

Trial Materials and Equipment

Trial-specific materials and equipment should be appropriately handled at close-out.

Depending on the trial, equipment may need to be returned, transferred, retained or otherwise managed according to sponsor instructions and applicable agreements.

Access to trial-specific systems may also need to be reviewed or withdrawn when it is no longer required.

Essential Records

Essential records should be reviewed to confirm that required trial documentation is appropriately maintained.

The investigator/institution and sponsor should retain their respective essential records in accordance with applicable regulatory requirements.

Records should remain complete, identifiable, accessible and appropriately protected for the required retention period.

The investigator/institution should know where its essential records are maintained and should inform the sponsor when required if responsibility for record retention or the storage location changes.

Outstanding Issues and Noncompliance

Outstanding trial issues should be identified and appropriately addressed during close-out.

This may include unresolved data queries, protocol deviations, safety-related documentation, investigational product discrepancies or other significant findings.

Where noncompliance has been identified, appropriate corrective and preventive actions should be documented when necessary.

Issues that cannot be completely resolved at the time of close-out should have an appropriate documented follow-up plan.

Safety and Required Reporting

Outstanding safety information should be appropriately reported and followed up according to the protocol and applicable regulatory requirements.

The investigator should also complete required reports, notifications or other information associated with completion or termination of trial activities at the site.

Requirements may differ between jurisdictions and according to the nature of the clinical trial.

Close-out Monitoring

Close-out monitoring helps confirm that applicable site responsibilities have been completed and that outstanding matters have been appropriately addressed.

Activities may include reviewing essential records, investigational product accountability, outstanding data or safety issues, trial materials and arrangements for record retention.

The approach to close-out should reflect the trial design, identified risks and applicable monitoring plan rather than relying on a single universal checklist for every clinical trial.

These activities should be conducted in accordance with applicable requirements and the ICH Good Clinical Practice guideline.

Close-out Documentation

Close-out activities should be appropriately documented.

A close-out monitoring report or other applicable documentation should record relevant close-out activities, findings and follow-up actions.

Documentation should provide evidence that the required close-out activities were performed and that unresolved matters, if any, have an appropriate follow-up process.

Record Retention

Closing an investigator site does not end the responsibility to retain required clinical trial records.

Essential records should be retained for the period required by applicable regulatory requirements and relevant agreements.

Records should remain accessible for authorised monitoring, audits or regulatory inspection when required.

Appropriate safeguards should continue to protect participant confidentiality and the integrity of trial information throughout the retention period.

Importance of Site Close-out in Clinical Research

Effective site close-out provides an orderly transition from active trial conduct to completion and long-term record retention.

It helps confirm that investigational products have been accounted for, essential records are appropriately maintained, outstanding issues are addressed and required reporting obligations have been considered.

Site close-out therefore represents more than the end of participant visits. It is an important quality and compliance activity that helps ensure that the investigator site completes its clinical trial responsibilities appropriately.

You may be interested in the programs below: